Myriad Genetics Stock Price, News & Analysis

Myriad Genetics announced the FDA approval of its BRACAnalysis CDx test as a companion diagnostic for HER2 negative high-risk early-stage breast cancer patients. This test identifies germline BRCA mutations and assists in determining eligibility for Lynparza (olaparib) treatment. The OlympiA trial demonstrated significant improvement in patient survival rates. This advancement enhances treatment options for breast cancer patients and underscores the growing role of genomics in clinical care.

Myriad Genetics, a leader in genetic testing, will participate in the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 9:50 a.m. ET. CEO Paul J. Diaz will discuss the impact of genetic insights on health equity, new commercial capabilities, and industry trends. The presentation will be available via a live audio webcast on Myriad's investor information page at www.myriad.com. Myriad Genetics is dedicated to improving patient care through genetic testing that influences disease risk assessment and treatment decisions.

Myriad Genetics, Inc. reported a 4% revenue increase to $160.8 million for Q4 2021, totaling $690.6 million for the year—a 24% annual rise. Excluding divested businesses, Q4 revenues rose 19% year-over-year. Despite COVID-19 challenges, the company improved its cash position to $398.8 million. Q4 GAAP EPS was $(0.10) and adjusted EPS $(0.02). Diagnostic volumes remained stable, with notable growth in prenatal and pharmacogenomics tests. The firm plans to launch several new products in 2022 and reiterated its revenue guidance of $670 - $700 million.

Myriad Genetics (NASDAQ:MYGN) announced the publication of a peer-reviewed analysis confirming that its GeneSight® Psychotropic test is more effective than single-gene testing in predicting sertraline metabolism for patients with major depressive disorder (MDD).

This study, featured in Psychiatry Research, utilized data from 124 patients, reinforcing gene-drug interaction insights for clinicians. The findings suggest that GeneSight could significantly improve treatment outcomes for patients using sertraline, a widely prescribed SSRI.

Myriad Genetics (NASDAQ: MYGN) will host its 2021 fourth-quarter earnings conference call on February 24, 2022, at 4:30 p.m. ET, coinciding with the release of its quarterly earnings prior to market opening. President and CEO Paul J. Diaz, along with CFO R. Bryan Riggsbee, will provide a financial overview and business update for the period ending December 31, 2021. Call-in details are provided for domestic and international callers. An archived replay will be available for seven days, and a live webcast will stream on the company's website.

Myriad Genetics, a leader in genetic testing and precision medicine, announced its participation in two major healthcare conferences. On Feb. 17, 2022, CFO R. Bryan Riggsbee will engage in a fireside chat at the virtual BTIG MedTech Conference at 12 p.m. ET. This will be followed by a discussion featuring President and CEO Paul J. Diaz and Riggsbee at the SVB Leerink Global Healthcare Conference on Feb. 18, 2022, at 11:20 a.m. ET. Interested parties can access live webcasts of these events via Myriad's investor information section at www.myriad.com.

On January 11, 2022, Paul J. Diaz, President and CEO of Myriad Genetics (NASDAQ: MYGN), will present at the 40th Annual J.P. Morgan Health Care Conference. The presentation, set for 2:15 p.m. ET, will focus on the company’s strategic transformation and growth plans. Diaz will highlight the increasing importance of genetic insights in healthcare, discussing new products that enhance health equity and improve disease detection and treatment. A live audio webcast of the event will be available through Myriad's website and other platforms.

Myriad Genetics announced the retirement of Jerry Lanchbury, Ph.D., as Chief Scientific Officer after over 19 years. A national search for his permanent successor is underway, with Lanchbury providing consulting services until the end of Q1 2022. Dale Muzzey, Ph.D., is promoted to Senior Vice President for Research and Development and will serve as interim CSO. The company emphasizes its commitment to scientific innovation and commercial capabilities during this transition. Myriad Genetics continues to lead in genetic testing and precision medicine.